From: The landscape overview of CD47-based immunotherapy for hematological malignancies
Drug Name | NCT Number | Sponsor | Protocol | Indication Detail | Enroll-ment | Age/Race/Healthy Volunteers | Phase | Status | Start Date | Design | Endpoint Types | Efficacy Results | Ref |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CC-90002 | NCT02641002 | Celgene Corp | CC-90002 | Subjects With AML and High-Risk MDS | 28 | Adults (18 and over) | Phase I | Terminted | 2016/3/1 | Interventional; Treatment; Open Label; Single Group Assignment | Safety; Efficacy; Pharmacokinetics | terminated (preliminary monotherapy data did not offer a sufficiently encouraging profile for further dose escalation/expansion) | [61] |
TJ011133 | NCT04202003 | I-Mab Biopharma Co Ltd | TJ011133 | r/r AML/MDS | 5 | Adults (18–79 years) | Phase I | Recruiting | 2020/3/25 | Interventional; Treatment; Non-Randomized; Open Label; Single Group Assignment | Efficacy | 20% achieved morphologic leukemia-free state | [62] |
Hu5F9-G4 | NCT03248479 | Gilead Sciences Inc | Hu5F9-G4; AZA | untreated AML/MDS | 68 | Adults (18 and over) | Phase I | Recruiting | 2017/9/8 | Interventional; Treatment; Non-Randomized; Open Label; Parallel Assignment | Safety; Efficacy; Pharmacokinetics | ORR: 79%; CR/CRi: 56% | [63] |
Hu5F9-G4 | NCT04435691 | MD Anderson Cancer Center | Hu5F9-G4; AZA; VEN | Patients (pts) with Newly Diagnosed AML | 23 | Adults (18 and over) | Phase I/II | Recruiting | 2020/7/28 | Interventional; Treatment; Open Label; Single Group Assignment | Safety; Efficacy | CR/CRi: 100% | [64] |
Hu5F9-G4 | NCT04435691 | MD Anderson Cancer Center | Hu5F9-G4; AZA; VEN | Patients (pts) with R/R-post-VEN failure AML | 13 | Adults (18 and over) | Phase I/II | Recruiting | 2020/7/28 | Interventional; Treatment; Open Label; Single Group Assignment | Safety; Efficacy | CR/CRi: 27% | [64] |
Hu5F9-G4 | NCT04435691 | MD Anderson Cancer Center | Hu5F9-G4; AZA; VEN | Patients (pts) with R/R-VEN naive AML | 8 | Adults (18 and over) | Phase I/II | Recruiting | 2020/7/28 | Interventional; Treatment; Open Label; Single Group Assignment | Safety; Efficacy | CR/CRi: 63% | [64] |